カテゴリー： QYResearch, 世界

世界のヘテロ接合性家族性高コレステロール血症薬市場 2019年

【英語タイトル】Global Heterozygous Familial Hypercholesterolemia Drug Market Professional Survey Report 2019

QYResearchが出版した調査資料（DATA909X08978）・商品コード：DATA909X08978
・発行会社（調査会社）：QYResearch
・発行日：2019年11月20日（※2024年版があります。お問い合わせください）
・ページ数：109
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥518,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,250 ⇒換算￥777,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,000 ⇒換算￥1,036,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※本調査レポートは、ヘテロ接合性家族性高コレステロール血症薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、ゲムカベンカルシウム、MGL-3196、ST-103、その他に、用途別には、クリニック、病院、その他にセグメント区分し、ヘテロ接合性家族性高コレステロール血症薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・ヘテロ接合性家族性高コレステロール血症薬の世界市場概要
・ヘテロ接合性家族性高コレステロール血症薬の製造コスト構成分析
・ヘテロ接合性家族性高コレステロール血症薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・ヘテロ接合性家族性高コレステロール血症薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・ヘテロ接合性家族性高コレステロール血症薬のセグメント分析（種類別）
（ゲムカベンカルシウム、MGL-3196、ST-103、その他）
・ヘテロ接合性家族性高コレステロール血症薬のセグメント分析（用途別）
（クリニック、病院、その他）
・ヘテロ接合性家族性高コレステロール血症薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Daewoong Co Ltd、Esperion Therapeutics Inc、Gemphire Therapeutics Inc、Madrigal Pharmaceuticals Inc、）
・ヘテロ接合性家族性高コレステロール血症薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...
【レポートの概要】

The global Heterozygous Familial Hypercholesterolemia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Heterozygous Familial Hypercholesterolemia Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Heterozygous Familial Hypercholesterolemia Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Heterozygous Familial Hypercholesterolemia Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Heterozygous Familial Hypercholesterolemia Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Daewoong Co Ltd
Esperion Therapeutics Inc
Gemphire Therapeutics Inc
Madrigal Pharmaceuticals Inc
…

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Gemcabene Calcium
MGL-3196
ST-103
Others

Segment by Application
Clinic
Hospital
Others

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Heterozygous Familial Hypercholesterolemia Drug
1.1 Definition of Heterozygous Familial Hypercholesterolemia Drug
1.2 Heterozygous Familial Hypercholesterolemia Drug Segment by Type
1.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Gemcabene Calcium
1.2.3 MGL-3196
1.2.4 ST-103
1.2.5 Others
1.3 Heterozygous Familial Hypercholesterolemia Drug Segment by Applications
1.3.1 Global Heterozygous Familial Hypercholesterolemia Drug Consumption Comparison by Applications (2014-2025)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Heterozygous Familial Hypercholesterolemia Drug Overall Market
1.4.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue (2014-2025)
1.4.2 Global Heterozygous Familial Hypercholesterolemia Drug Production (2014-2025)
1.4.3 North America Heterozygous Familial Hypercholesterolemia Drug Status and Prospect (2014-2025)
1.4.4 Europe Heterozygous Familial Hypercholesterolemia Drug Status and Prospect (2014-2025)
1.4.5 China Heterozygous Familial Hypercholesterolemia Drug Status and Prospect (2014-2025)
1.4.6 Japan Heterozygous Familial Hypercholesterolemia Drug Status and Prospect (2014-2025)
1.4.7 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Status and Prospect (2014-2025)
1.4.8 India Heterozygous Familial Hypercholesterolemia Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Heterozygous Familial Hypercholesterolemia Drug
2.3 Manufacturing Process Analysis of Heterozygous Familial Hypercholesterolemia Drug
2.4 Industry Chain Structure of Heterozygous Familial Hypercholesterolemia Drug

3 Development and Manufacturing Plants Analysis of Heterozygous Familial Hypercholesterolemia Drug
3.1 Capacity and Commercial Production Date
3.2 Global Heterozygous Familial Hypercholesterolemia Drug Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Heterozygous Familial Hypercholesterolemia Drug
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Heterozygous Familial Hypercholesterolemia Drug Production and Capacity Analysis
4.2 Heterozygous Familial Hypercholesterolemia Drug Revenue Analysis
4.3 Heterozygous Familial Hypercholesterolemia Drug Price Analysis
4.4 Market Concentration Degree

5 Heterozygous Familial Hypercholesterolemia Drug Regional Market Analysis
5.1 Heterozygous Familial Hypercholesterolemia Drug Production by Regions
5.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Production by Regions
5.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Regions
5.2 Heterozygous Familial Hypercholesterolemia Drug Consumption by Regions
5.3 North America Heterozygous Familial Hypercholesterolemia Drug Market Analysis
5.3.1 North America Heterozygous Familial Hypercholesterolemia Drug Production
5.3.2 North America Heterozygous Familial Hypercholesterolemia Drug Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Heterozygous Familial Hypercholesterolemia Drug Import and Export
5.4 Europe Heterozygous Familial Hypercholesterolemia Drug Market Analysis
5.4.1 Europe Heterozygous Familial Hypercholesterolemia Drug Production
5.4.2 Europe Heterozygous Familial Hypercholesterolemia Drug Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Heterozygous Familial Hypercholesterolemia Drug Import and Export
5.5 China Heterozygous Familial Hypercholesterolemia Drug Market Analysis
5.5.1 China Heterozygous Familial Hypercholesterolemia Drug Production
5.5.2 China Heterozygous Familial Hypercholesterolemia Drug Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Heterozygous Familial Hypercholesterolemia Drug Import and Export
5.6 Japan Heterozygous Familial Hypercholesterolemia Drug Market Analysis
5.6.1 Japan Heterozygous Familial Hypercholesterolemia Drug Production
5.6.2 Japan Heterozygous Familial Hypercholesterolemia Drug Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Heterozygous Familial Hypercholesterolemia Drug Import and Export
5.7 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Market Analysis
5.7.1 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Production
5.7.2 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Import and Export
5.8 India Heterozygous Familial Hypercholesterolemia Drug Market Analysis
5.8.1 India Heterozygous Familial Hypercholesterolemia Drug Production
5.8.2 India Heterozygous Familial Hypercholesterolemia Drug Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Heterozygous Familial Hypercholesterolemia Drug Import and Export

6 Heterozygous Familial Hypercholesterolemia Drug Segment Market Analysis (by Type)
6.1 Global Heterozygous Familial Hypercholesterolemia Drug Production by Type
6.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type
6.3 Heterozygous Familial Hypercholesterolemia Drug Price by Type

7 Heterozygous Familial Hypercholesterolemia Drug Segment Market Analysis (by Application)
7.1 Global Heterozygous Familial Hypercholesterolemia Drug Consumption by Application
7.2 Global Heterozygous Familial Hypercholesterolemia Drug Consumption Market Share by Application (2014-2019)

8 Heterozygous Familial Hypercholesterolemia Drug Major Manufacturers Analysis
8.1 Daewoong Co Ltd
8.1.1 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
8.1.2 Daewoong Co Ltd Product Introduction, Application and Specification
8.1.3 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Esperion Therapeutics Inc
8.2.1 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
8.2.2 Esperion Therapeutics Inc Product Introduction, Application and Specification
8.2.3 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Gemphire Therapeutics Inc
8.3.1 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
8.3.2 Gemphire Therapeutics Inc Product Introduction, Application and Specification
8.3.3 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Madrigal Pharmaceuticals Inc
8.4.1 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
8.4.2 Madrigal Pharmaceuticals Inc Product Introduction, Application and Specification
8.4.3 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served

9 Development Trend of Analysis of Heterozygous Familial Hypercholesterolemia Drug Market
9.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Trend Analysis
9.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size (Volume and Value) Forecast 2019-2025
9.2 Heterozygous Familial Hypercholesterolemia Drug Regional Market Trend
9.2.1 North America Heterozygous Familial Hypercholesterolemia Drug Forecast 2019-2025
9.2.2 Europe Heterozygous Familial Hypercholesterolemia Drug Forecast 2019-2025
9.2.3 China Heterozygous Familial Hypercholesterolemia Drug Forecast 2019-2025
9.2.4 Japan Heterozygous Familial Hypercholesterolemia Drug Forecast 2019-2025
9.2.5 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Forecast 2019-2025
9.2.6 India Heterozygous Familial Hypercholesterolemia Drug Forecast 2019-2025
9.3 Heterozygous Familial Hypercholesterolemia Drug Market Trend (Product Type)
9.4 Heterozygous Familial Hypercholesterolemia Drug Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Heterozygous Familial Hypercholesterolemia Drug Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Heterozygous Familial Hypercholesterolemia Drug
Table Global Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Heterozygous Familial Hypercholesterolemia Drug Production Market Share by Types in 2018
Figure Gemcabene Calcium Product Picture
Figure MGL-3196 Product Picture
Figure ST-103 Product Picture
Figure Others Product Picture
Table Global Heterozygous Familial Hypercholesterolemia Drug Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Heterozygous Familial Hypercholesterolemia Drug Consumption Market Share by Applications in 2018
Figure Clinic
Figure Hospital
Figure Others
Figure Global Heterozygous Familial Hypercholesterolemia Drug Revenue (Million USD) (2014-2025)
Figure Global Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs) (2014-2025)
Figure North America Heterozygous Familial Hypercholesterolemia Drug Market Size (Million USD) (2014-2025)
Figure Europe Heterozygous Familial Hypercholesterolemia Drug Market Size (Million USD) (2014-2025)
Figure China Heterozygous Familial Hypercholesterolemia Drug Market Size (Million USD) (2014-2025)
Figure Japan Heterozygous Familial Hypercholesterolemia Drug Market Size (Million USD) (2014-2025)
Figure Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Market Size (Million USD) (2014-2025)
Figure India Heterozygous Familial Hypercholesterolemia Drug Market Size (Million USD) (2014-2025)
Table Heterozygous Familial Hypercholesterolemia Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Heterozygous Familial Hypercholesterolemia Drug in 2018
Figure Manufacturing Process Analysis of Heterozygous Familial Hypercholesterolemia Drug
Figure Industry Chain Structure of Heterozygous Familial Hypercholesterolemia Drug
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Heterozygous Familial Hypercholesterolemia Drug Manufacturing Plants Distribution
Table Heterozygous Familial Hypercholesterolemia Drug Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Heterozygous Familial Hypercholesterolemia Drug Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs) of Major Manufacturers (2014-2019)
Table Heterozygous Familial Hypercholesterolemia Drug Production Market Share of Major Manufacturers (2014-2019)
Figure Heterozygous Familial Hypercholesterolemia Drug Production Share by Manufacturers in 2018
Table Heterozygous Familial Hypercholesterolemia Drug Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share of Major Manufacturers (2014-2019)
Figure Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Manufacturers in 2018
Table Heterozygous Familial Hypercholesterolemia Drug Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Heterozygous Familial Hypercholesterolemia Drug Production by Regions 2014-2019 (K Pcs)
Table Global Heterozygous Familial Hypercholesterolemia Drug Production Market Share by Regions 2014-2019
Figure Global Heterozygous Familial Hypercholesterolemia Drug Production Market Share by Regions in 2018
Table Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Regions 2014-2019 (Million USD)
Table Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Regions 2014-2019
Figure Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Regions in 2018
Table Global Heterozygous Familial Hypercholesterolemia Drug Consumption by Regions 2014-2019 (K Pcs)
Table Global Heterozygous Familial Hypercholesterolemia Drug Consumption Market Share by Regions 2014-2019
Figure North America Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure North America Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table North America Heterozygous Familial Hypercholesterolemia Drug Production, Consumption Import and Export (K Pcs)
Figure Europe Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Heterozygous Familial Hypercholesterolemia Drug Production, Consumption Import and Export (K Pcs)
Figure China Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure China Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table China Heterozygous Familial Hypercholesterolemia Drug Production, Consumption Import and Export (K Pcs)
Figure Japan Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Heterozygous Familial Hypercholesterolemia Drug Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Production, Consumption Import and Export (K Pcs)
Figure India Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure India Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table India Heterozygous Familial Hypercholesterolemia Drug Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Heterozygous Familial Hypercholesterolemia Drug Market Share by Application (2014-2019)
Figure Global Value (Consumption) Heterozygous Familial Hypercholesterolemia Drug Market Share by Application (2014-2019)
Table Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
Table Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Product Introduction, Application and Specification
Table Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate (2014-2019)
Table Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production Market Share (2014-2019)
Figure Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share (2014-2019)
Table Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Main Business and Markets Served
Table Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
Table Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Introduction, Application and Specification
Table Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate (2014-2019)
Table Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Market Share (2014-2019)
Figure Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share (2014-2019)
Table Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Main Business and Markets Served
Table Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
Table Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Introduction, Application and Specification
Table Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate (2014-2019)
Table Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production Market Share (2014-2019)
Figure Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share (2014-2019)
Table Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Main Business and Markets Served
Table Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production Sites and Area Served
Table Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Product Introduction, Application and Specification
Table Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate (2014-2019)
Table Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production Market Share (2014-2019)
Figure Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share (2014-2019)
Table Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Main Business and Markets Served
Figure Global Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Heterozygous Familial Hypercholesterolemia Drug Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Heterozygous Familial Hypercholesterolemia Drug Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Heterozygous Familial Hypercholesterolemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Heterozygous Familial Hypercholesterolemia Drug by Type (2019-2025)
Table Global Consumption (K Pcs) of Heterozygous Familial Hypercholesterolemia Drug by Application (2019-2025)
Table Heterozygous Familial Hypercholesterolemia Drug Distributors List
Table Heterozygous Familial Hypercholesterolemia Drug Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Daewoong Co Ltd、Esperion Therapeutics Inc、Gemphire Therapeutics Inc、Madrigal Pharmaceuticals Inc、

★調査レポート[世界のヘテロ接合性家族性高コレステロール血症薬市場 2019年] (コード：DATA909X08978)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のヘテロ接合性家族性高コレステロール血症薬市場 2019年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の退形成性乏突起膠腫薬市場 2019年
    DATA909X03539 / QYResearch / 2019年11月15日 / ※本調査レポートは、退形成性乏突起膠腫薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、CDX-1401、デパツキシズマブマフォドチン、フルシトシン、その他に、用途別には、病院、クリニック、研究センターにセグメント区分し、退形成性乏突起膠腫薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・退形成性乏突起膠腫薬の世界市場概要 ・退形成性乏突起膠腫薬の製造コスト構成分析 ・退形成性乏突起膠腫薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・退形成性乏突起膠腫薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・退形成性乏突起膠腫薬のセグメント分析（種類別） （CDX-1401、デパツキシズマブマフォドチン、フルシトシン、その他）...The global Anaplastic Oligoastrocytoma Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Anaplastic Oligoastrocytoma Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anaplastic Oligoastrocytoma Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Anaplastic Oligoastrocytoma Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界のファンコニ貧血薬市場 2019年
    DATA909X07597 / QYResearch / 2019年11月15日 / ※本調査レポートは、ファンコニ貧血薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、エルトロンボパグオラミン、EXG-34217、ファンカレン、その他に、用途別には、病院、診療所、その他にセグメント区分し、ファンコニ貧血薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・ファンコニ貧血薬の世界市場概要 ・ファンコニ貧血薬の製造コスト構成分析 ・ファンコニ貧血薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・ファンコニ貧血薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・ファンコニ貧血薬のセグメント分析（種類別） （エルトロンボパグオラミン、EXG-34217、ファンカレン、その他）...The global Fanconi Anemia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Fanconi Anemia Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Fanconi Anemia Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Fanconi Anemia Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の平滑筋肉腫薬市場 2019年
    DATA909X10490 / QYResearch / 2019年11月20日 / ※本調査レポートは、平滑筋肉腫薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、AL-3818、BGB-290、C-21、その他に、用途別には、クリニック、病院、その他にセグメント区分し、平滑筋肉腫薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・平滑筋肉腫薬の世界市場概要 ・平滑筋肉腫薬の製造コスト構成分析 ・平滑筋肉腫薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・平滑筋肉腫薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・平滑筋肉腫薬のセグメント分析（種類別） （AL-3818、BGB-290、C-21、その他）...The global Leiomyosarcoma Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Leiomyosarcoma Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Leiomyosarcoma Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Leiomyosarcoma Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes their Leiomyosarcoma Drug manufacturing...
  • 世界の血友病A治療薬市場 2019年
    DATA909X08942 / QYResearch / 2019年11月20日 / ※本調査レポートは、血友病A治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、ATXF-8117、BAY-1093884、BIVV-001、BS-027125、コンシズマブ、CSL-689、その他に、用途別には、クリニック、病院、ASCにセグメント区分し、血友病A治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・血友病A治療薬の世界市場概要 ・血友病A治療薬の製造コスト構成分析 ・血友病A治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・血友病A治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・血友病A治療薬のセグメント分析（種類別） （ATXF-8117、BAY-1093884、BIVV-001、BS-027125、コンシズマブ、CSL-689、その他）...The global Hemophilia A Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Hemophilia A Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hemophilia A Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Hemophilia A Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の女性用避妊薬市場 2019年
    DATA909X07649 / QYResearch / 2019年11月15日 / ※本調査レポートは、女性用避妊薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、AG-890、アンフォラ、BAY-1007626、ドロスピレノン、その他に、用途別には、クリニック、病院、在宅ケアにセグメント区分し、女性用避妊薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・女性用避妊薬の世界市場概要 ・女性用避妊薬の製造コスト構成分析 ・女性用避妊薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・女性用避妊薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・女性用避妊薬のセグメント分析（種類別） （AG-890、アンフォラ、BAY-1007626、ドロスピレノン、その他）...The global Female Contraception Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Female Contraception Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Female Contraception Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Female Contraception Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の心筋梗塞治療薬市場 2019年
    DATA909X11786 / QYResearch / 2019年11月20日 / ※本調査レポートは、心筋梗塞治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、JVS-200、KR-33028、AMRS-001、ANG-4011、Balixafortide、CAP-1002、Cenderitide、その他に、用途別には、研究センター、病院、クリニックにセグメント区分し、心筋梗塞治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・心筋梗塞治療薬の世界市場概要 ・心筋梗塞治療薬の製造コスト構成分析 ・心筋梗塞治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・心筋梗塞治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・心筋梗塞治療薬のセグメント分析（種類別） （JVS-200、KR-33028、AMRS-001、ANG-4011、Balixafortide、CAP-1002、Cenderitide、その他）...The global Myocardial Infarction Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Myocardial Infarction Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myocardial Infarction Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Myocardial Infarction Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の気管支肺異形成薬市場 2019年
    DATA909X04840 / QYResearch / 2019年11月15日 / ※本調査レポートは、気管支肺異形成薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、ブデソニド、クエン酸カフェイン、CG-100、その他に、用途別には、病院、診療所、その他にセグメント区分し、気管支肺異形成薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・気管支肺異形成薬の世界市場概要 ・気管支肺異形成薬の製造コスト構成分析 ・気管支肺異形成薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・気管支肺異形成薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・気管支肺異形成薬のセグメント分析（種類別） （ブデソニド、クエン酸カフェイン、CG-100、その他）...The global Bronchopulmonary Dysplasia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Bronchopulmonary Dysplasia Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bronchopulmonary Dysplasia Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Bronchopulmonary Dysplasia Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...

    • ◆H&Iグローバルリサーチのお客様（例）◆